Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

February 29, 2016

Study Completion Date

January 31, 2019

Conditions
Atopic Dermatitis
Interventions
DRUG

ILV-094

IV infusion of ILV-094

DRUG

Placebo Comparator

Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of a placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).

Trial Locations (1)

10065

The Rockefeller University, New York

All Listed Sponsors
collaborator

Icahn School of Medicine at Mount Sinai

OTHER

lead

Rockefeller University

OTHER

NCT01941537 - Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis | Biotech Hunter | Biotech Hunter